ArticleCardiovascular diabetology2020

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.

Sin-Hee Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.